A statement released earlier today by UBS AG about Essilor International (EPA:EI) bumps the target price to 130.00EUR
- Updated: November 25, 2016
Yesterday Essilor International (EPA:EI) traded 0.00% even at 98.86EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last stock close price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 0
UBS AG bumped up the target of Essilor International (EPA:EI) to 130.00EUR indicating a possible upside of 0.31%.
Previously on 11/25/2016, UBS AG reported about Essilor International (EPA:EI) raised the target price from 0.00EUR to 130.00EUR. At the time, this indicated a possible upside of 0.32%.
See Chart Below
Essilor International has a 52 week low of 0.00EUR and a 52 week high of 0.00EUR Essilor International’s market capitalization is presently 0 EUR.
General Company Details For Essilor International (EPA:EI)
Essilor International SA, formerly Essilor International Compagnie Generale D'Optique SA, is an ophthalmic optics company. The Company designs, manufactures and markets a range of lenses to improve and protect eyesight. It also develops and markets equipment for prescription laboratories, and instruments and services for eye care professionals. It operates through three segments: Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. It is a North American provider of non-prescription reading glasses. It also sells non-prescription sunglasses. It has approximately 32 plants, over 490 prescription laboratories, edging facilities and local distribution centers, and over five research and development centers across the world. The Company designs, manufactures and customizes corrective lenses. The Company provides a range of lenses for correcting myopia, hyperopia, astigmatism and presbyopia. It operates through MyOptique Group.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.